+

WO2005080574A1 - Modele de souris transgenique et procede d'evaluation de carences en glucocerebrosidase - Google Patents

Modele de souris transgenique et procede d'evaluation de carences en glucocerebrosidase Download PDF

Info

Publication number
WO2005080574A1
WO2005080574A1 PCT/CA2005/000266 CA2005000266W WO2005080574A1 WO 2005080574 A1 WO2005080574 A1 WO 2005080574A1 CA 2005000266 W CA2005000266 W CA 2005000266W WO 2005080574 A1 WO2005080574 A1 WO 2005080574A1
Authority
WO
WIPO (PCT)
Prior art keywords
recombinase
mouse
glucocerebrosidase
gene
recombinase recognition
Prior art date
Application number
PCT/CA2005/000266
Other languages
English (en)
Inventor
Lorne Clarke
Graham Sinclair
Francis Choy
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of WO2005080574A1 publication Critical patent/WO2005080574A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • This application relates to a mouse model and to methods of using the mouse model in the evaluation of glucocerbrosidase deficiences, such as Gaucher Disease.
  • glucocerebrosidase (GBA, acid ⁇ - glucosidase) EC 3.2.1.45) underlies the autosomal recessive disorder, Gaucher disease.
  • GAA glucocerebrosidase
  • This disorder represents the most common lysosomal storage disorder and is the first lysosomal disorder to be treated by direct enzyme replacement strategies.
  • the global disease incidence is estimated to be 1/50,000 to 1/100,000 individuals, although incidence rates increase to 1/850 in those of Ashkenazi Jewish descent.
  • type 1 non-neuronopathic
  • type 2 acute neuronopathic
  • type 3 sub-acute neuronopathic
  • type 1 represents the most prevalent form. While enzyme replacement strategies have been effective in treating some of the complications of type 1 disease, this form of therapy is not generally helpful for type 2 or 3 patients. All forms of this disorder share a group of classic "Gaucher" symptoms consisting of hepatosplenomegaly, pancytopenia, frequent bone crises, and the presence of lipid engorged macrophages known as Gaucher cells. Types 2 and 3 Gaucher disease also include neuronal loss leading to extensive neurological dysfunction in those affected (Beutler and Grabowski, 2001).
  • mice with common point mutations or chemically induced models for GBA deficiency have led to animals with no obvious phenotype.
  • Xu et al. Amer. J. Pathol 163: 2093-2101 (2003) disclose mouse models containing specific point mutations in the GBA gene. Mice with these mutations are viable, and exhibit phenotypes in which both glucocerebrosidase storage and the production of small numbers of lipid-engorged Gaucher cells are observed. These phenotypes develop only to a limited extent, however, and are only reported after at least 7 months of life.
  • the present invention provides a recombinant mouse model, wherein the genome of the mouse is modified by introduction of paired recombinase recognition sites integrated in the glucocerebrosidase gene in the genome of the transgenic mouse.
  • the recombinase recognition sites flank a portion of the glucocerebrosidase gene including as least one exon of the glucocerebrosidase gene and are oriented such that the portion of the glucocerebrosidase gene is excised in the presence of a recombinase that recognizes the paired recombinase recognition sites.
  • the genome of the mouse is also modified by introduction of a recombinase transgene encoding the recombinase that recognizes the paired recombinase recognition sites.
  • the recombinase transgene may be introduced by crossing the mouse of the invention having recombinase cites integrated in the glucocerebrosidase gene with a recombinant mouse known to express the recombinase to produce progeny mice, which are themselves within the scope of the invention, having both the modified glucocerebrosidase gene and a recombinase transgene.
  • the recombinase transgene can be introduced to mice in accordance with the invention at a selected developmental stage, for example using a viral vector containing the recombinase transgene.
  • Other methods for exposing cells to recombinase may also be used.
  • the recombinase recognition sites are be recognized by Flpe recombinase or Cre recombinase.
  • Expression of the recombinase encoded by the transgene is under the control of tissue-specific promoter.
  • the tissue-specific promoter may be specific to hematopoietic cells or to CNS-specific promoter.
  • the model mouse system of the invention is useful for evaluation of glucose cerebrosidase deficiencies and offers greater versatility over the Xu et al. mouse.
  • the mouse model of the invention can be used to evaluate different types of conditions associated with glucocerebrosidase deficiency because me expression of the recombinase, and hence the occurrence of a glucocerebrosidase deficiency, can be controlled in a tissue-specific manner. Further, because the onset of glucocerebrosidase deficiency can be controlled temporally, the affects of the deficiency can be observed earlier, including in utero, or later, as desired for a given condition.
  • This model also has the capability of providing a resource of murine cells lines and/or tissue extracts, not restricted to the following examples: bone marrow, fibroblasts, neural stem cells and hepatocytes for invitro investigations of GBA deficiency and/or invitro CRE excision studies.
  • Fig 1A shows the native exon structure of GBA
  • Fig. IB shows a targeting construct in accordance with the invention
  • Fig. 1C shows the targeting construct after removal of the selection marker
  • Fig. ID shows the construct after excision of a portion of the GBA gene.
  • a "recombinase” is an enzyme that catalyzes new phosphodiester bonds between a pair of short, unique DNA target sequences, or "recombinase recognition sites".
  • recombinase enzymes include the Cre enzyme, derived from bacteriophage PI, which recognizes lox sites as described in US Patent No. 4,959,317, which is incorporated herein by reference; and the FLP enzyme, derived from Saccharomyces cerevisiae, which recognizes ERE sites as described in US Patent No. 6,774,279, which is incorporated herein by reference.
  • the lox? recognition site has the sequence
  • the FRT recognition site has the sequence
  • GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC (Seq. ID No. 2).
  • recombinase mouse refers to a mouse that has a transgene for a recombinase.
  • Recombinase mice are known in the art, and are commercially available. For example, The Jackson Laboratory, offers for sale numerous mice strains which express Cre or FLP in different tissues and under the control of different promoters.
  • tissue specific expression refers to expression of the recombinase in a subsets of the tissues, as opposed to expression across all tissues in the mouse. Tissue specific expression does require expression in only one tissue.
  • the invention described herein utilizes refinements of recombinase-mediated gene targeting strategies to produce a murine model of glucocerebrosidase deficiency. This can be controlled in a tissue specific and development specific manner. By introducing the recombinase (for example Cre) into the system in a spacio-temporally controlled manner, the lethal phenotypes observed in other attempted GBA knockout models are avoided.
  • the mouse model of the invention is homozygous for recombinase site insertions flanking part of the glucocerebrosidase (GBA) gene.
  • the mouse model gives researchers the ability to control temporal GBA expression and tissue specific GBA expression by exposing said animal, or specific tissues within the animal, to recombinases such as Cre or Flpe.
  • the recombinase will remove part of the GBA gene, thus eliminating or attenuating GBA activity and allowing the phenotype of Gaucher disease and/or other phenotypic features of GBA deficiency to develop within the animal.
  • the lethal development aspects that occur from standard or prior art embryonic stem cell GBA knockout strategies will be prevented, and non-lethal knock out or attenuation will occur only when investigator directed recombinase exposure occurs. Figs.
  • FIG. 1 A-D show a GBA locus and targeting construct in accordance with the invention, and are illustrative of the method and recombinant genome of the mice of the invention .
  • Fig. 1A shows the native exon structure of GBA is depicted in black and the MTX (metaxin) locus in grey. The nucleotide numbering is in reference to Genbank Accession # AY115108 (Seq. ID No. : 3) and the Sea I cutsites and external probe used for Southern blot analyses are also noted.
  • Fig. IB shows te targeting construct including a neomycin resistance marker (Neo 1 ), Cre recognition sites (loxP) and Flpe recognition sites (FRT).
  • Fig. 1C shows the targeted locus following Flpe-mediated removal of the neomycin resistance marker. This sequence differs from the native locus only by the addition of one FRT and two loxP sites.
  • Fig. ID shows the final recombined, non-functional, GBA knockout allele following Cre recombination and excision of exons 9-11.
  • a sequence spanning at least a portion of the GBA gene and at least a portion of the MTX gene is replaced with a construct such as that shown in Fig. IB.
  • the construct comprises, from the 5' to the 3' end, a first portion of the GBA gene, a first recombinase recognition site, a second portion of the GBA gene, a second recombinase recognition site, recognized by the same recombinase as the first recombinase recognition site, and optionally a third portion of the GBA gene.
  • a third portion of the GBA gene there is no third portion of the GBA gene because the excised portion of the gene is the 3' terminal exons (9-11). However, interior exons could also be excised.
  • the first and second recombinase recognition sites are loxP recognition sites.
  • any pair of recombinase recognition sites oriented for excision (deletion) of the intervening sequence could be utilized.
  • a third recombinase recognition site that is targeted by a different recombinase than the first and second recognition sites, a marker gene, and a fourth recombinase recognition site of the same type as the third recombinase recognition site.
  • the third and fourth recombinase recognition sites are FRT sites, but again all that is important is the difference.
  • the marker shown is Neo r , but any resistance or other selectable marker could be used.
  • IB is introduced into totipotent mouse embryonic stem cells for homologous recombination at the GBA locus.
  • the selection marker e.g. Neo 1
  • the selected cells are then treated to introduce an recombinase expression vector (an Flpe recombinase in the case of the construct in Fig. IB) to remove the selection marker, leaving embryonic stem cells with a structure as shown in Fig. lC.
  • These cells were screened to select for sensitive cells (e.g. Neo sensitive cells).
  • These cells are the introduced into blastocyst to produce recombinant mice of the invention. These mice will produce a functional glucocerebrosidase product until such time as the appropriate recombinase (Cre in the case of the construct in Fig. 1C) is present.
  • METHODS OF EXPOSING THE MOUSE MODEL TO RECOMBINASE Recombinase exposure can occur by crossing the animal described herein with a recombinase mouse with known recombinase expression patterns, or exposing the animal to viral vectors capable of infecting the animals cells and tissues and delivering a functional recombinase gene.
  • Other methods for gene delivery include liposome delivery of recombinase genes, or other transfection techniques described in the art. Expression of recombinase can be controlled through various means.
  • CRE recombinase in an inducible manner to provide temporal, spatial and cell-type specific control of Cre-mediated DNA recombination in transgenic mice are described in Utomo, et al., Nature Biotechnol.(l 999), 17, 1091-1096, which is incorporated herein by reference. These options for control provide great diversity for the model of the invention. See also, Branda et al., Developmental Cell (2004). 6(l):7-28, which is incorporated herein by reference. Mechanisms for delivery of recombinase proteins per se to target cells also exist. A review of such methods is provided in Cleland et al.
  • electroporation can be used. Although this method was first used to introduce foreign DNA into mammalian, plant and bacterial cells, it will also permit the introduction of proteins.
  • Cells suspended in a buffered solution of the purified protein of interest are placed in a pulsed electrical field. Brief, high-voltage electric pulses result in the formation of small (nanometer-sized) pores in the cell membrane. Proteins enter the cell via these small pores or during the process of membrane reorganization as the pores close and the cell returns to its normal state. The efficiency of delivery is dependent upon the strength of the applied electrical field, the length of the pulses, temperature and the composition of the buffered medium.
  • Electroporation is successful with a variety of cell types, even some cell lines that are resistant to other delivery methods, although the overall efficiency is often quite low.
  • the electroporation process can be damaging to the cells, frequently killing the majority of the cells used. As a result, considerable optimization is required to obtain efficient delivery and n ⁇ iimize cell death.
  • some primary lymphocyte cell lines remain refractory even to electroporation unless partially activated, eliminating the possibility of any downstream studies relevant to cell activation or cell cycle control.
  • Microinjection may also be used to introduce recombinase proteins. Microinjection was first used to introduce femtoliter volumes of DNA directly into the nucleus of a cell, where it can be integrated directly into the host cell genome, thus creating an established cell line bearing the sequence of interest.
  • Proteins such as antibodies and mutant proteins can also be directly delivered into cells via microinjection to determine their effects on cellular processes first hand.
  • Microinjection has the advantage of introducing macromolecules directly into the cell, thereby bypassing exposure to potentially undesirable cellular compartments such as low-pH endosomes.
  • the art of microinjection requires extensive training to master and specialized equipment including micropipette pullers, microinjectors and inverted microscopes equipped with micromanipulators.
  • Viral protein fusions can be used to introduce recombinases.
  • proteins and small peptides have the ability to transduce or travel through biological membranes independent of classical receptor- or endocytosis-mediated pathways.
  • proteins examples include the HIV-1 TAT protein, the herpes simplex vims 1 (HSV-1) DNA-binding protein VP22, and the Drosophila Antennapedia (Antp) homeotic transcription factor.
  • the small protein transduction domains (PTDs) from these proteins can be fused to other macromolecules, peptides or proteins to successfully transport them into a cell. Sequence alignments of the transduction domains from these proteins show a high basic amino acid content (Lys and Arg) which may facilitate interaction of these regions with negatively charged lipids in the membrane. Secondary structure analyses show no consistent structure between all three domains. The advantages of using fusions of these transduction domains is that protein entry is rapid, concentration-dependent and appears to work with difficult cell types.
  • each of the three commonly used PTDs has its own unique considerations. While fusion proteins of >1,000 residues is possible with the TAT and VP22 approaches, the size of the protein being transduced as an Antp fusion is limited to ⁇ 100 residues.
  • a major disadvantage of creating a TAT fusion protein is that the transduced protein is denatured or inactivated as it passes through the membrane. Thus, upon entry into the cell, the protein needs to be properly refolded to regain its biological activity.
  • the VP22 strategy is used as an indirect method in that the vector bearing the fusion construct is transfected into cells where the fusion protein is made and the resulting protein then transduces into surrounding cells.
  • a drawback to all of the PTD-mediated protein delivery systems is that the transduction domain must be covalently attached to the protein being delivered, either by creating a DNA construct in a specially designed vector or by chemically cross-linking the protein and PTD via functional groups on each molecule.
  • Liposomes have been rigorously investigated as vehicles to deliver oligonucleotides, DNA (gene) constructs and small drug molecules into cells. Certain lipids, when placed in an aqueous solution and sonicated, form closed vesicles consisting of a circularized lipid bilayer surrounding an aqueous compartment.
  • vesicles or liposomes can be formed in a solution containing the molecule to be delivered.
  • canonic liposomes can spontaneously and efficiently fonn complexes with DNA, with the positively charged head groups on the lipids interacting with the negatively charged backbone of the DNA.
  • the exact composition and/or mixture of cationic lipids used can be altered, depending upon the macromolecule of interest and the cell type used.
  • the cationic liposome strategy has also been applied successfully to protein delivery. Because proteins are more heterogeneous than DNA, the physical characteristics of the protein such as its charge and hydrophobicity will influence the extent of its interaction with the cationic lipids.
  • Pro-JectTM Protein Transfection Reagent (Pierce, Product # 89850) which utilizes a cationic lipid formulation that is noncytotoxic and is capable of delivering a variety of proteins into numerous cell types.
  • the protein being studied is mixed with the liposome reagent and is overlayed onto cultured cells.
  • the liposome:protein complex fuses with the cell membrane or is internalized via an endosome.
  • the protein or macromolecule of interest is released from the complex into the cytoplasm free of lipids and escaping lysosomal degradation.
  • the noncovalent nature of these complexes is a major advantage of the liposome strategy as the delivered protein is not modified and therefore maintains its activity. As with all direct protein delivery systems, the time saved is significant over the indirect DNA transfection procedures.
  • the animal described herein can be used for evaluating therapeutic agents for use in treating Gaucher disease or other disease states caused by GBA deficiency.
  • the screening protocol involves therapies to provide glucocerebrosidase activity to those tissues, or whole animals, in which GBA activity has been removed by exposure of the GBA gene to recombinases capable of recognizing the appropriate sites flanking the GBA gene.
  • the ability of the therapy to reconstitute GBA activity can be assessed.
  • the mice of the invention are used to monitor the influx of lipid laden macrophages to the bone marrow of GBA compromised recombinant mice.
  • potential treatments for chronic bone disease and/or chronic bone pain can also be evaluated using the recombinant mouse described herein.
  • An effective therapy would be marked by lower bone migration of macrophages and/or marked lessening of the macrophages laden with lipid.
  • other therapeutics for pathologies associated with Gaucher such as hepatomegaly (abdominal pain), splenomegaly (enlarged spleen), cardiac alterations, pulmonary alterations, and neurologic manifestations could be screened.
  • the recombinant animal described herein can also be used to evaluate the ability of a targeting system to deliver a therapeutic agent to selected tissues or organs which have been compromised by selective recombinase removal of the GBA gene.
  • a therapeutics' potential to cleave glucosylcera ide or alter the glucosylcera ide pathway can be monitored and evaluated, whether the therapeutic is an in vivo or ex vivo gene therapy technique, enzyme replacement therapy, or some form of compound capable of cleaving, or enhancing the cleavage or clearance of glucosylceramide, stabilizing a mutated endogenous GBA protein, or other means by which glucosylceramide levels can be altered.
  • mice of this invention relate to studies directed to the understanding of the role that GBA its substrates and products play, in metabolism in general. Important aspects would include, but not be restricted to, the role of GBA in maintenance of skin permeability and neuronal function.
  • the invention will now be further illustrated with reference to the following non-limiting examples.
  • Example 1 A targeting construct was designed to utilize the pFLRT3 vector containing both Cre and Flpe recombinase recognition sites for these engineering steps. This allows for the removal of the Neomycin selectable marker using Flpe-recombinase, leaving the GBA locus intact with only the addition of two CRE recombinase sites, and a single FRT site.
  • the targeting construct pFLRTGBA (Fig. 1A) was designed such that a 1.2kb PCR fragment of the GBA gene obtained using Seq. ID Nos. 3 and 4 as primers, encoding the active site of the protein (exons 9-11) would be flanked by loxP sites and excised in the presence of the Cre recombinase.
  • a 6.7kb fragment encoding the 5'UTR and exons 1-8 of GBA was obtained using primers of Seq. ID Nos. 5 and 6, and cloned-in using PCR-based compatible linkers at the extremities and a large subcloned fragment for the remainder of this long arm.
  • a 2.9kb fragment containing exons 8-4 of the Metaxin gene was introduced using a PCR-based approach and primers of Seq ID Nos: 7 and 8.
  • MXT is contiguous (on the reverse strand) with GBA on mouse chromosome 3 and its function is required for viability.
  • Example 2 The development of a knockout mouse utilizes the introduction of the targeting vector to totipotent mouse ES cells for homologous recombination of the transgene at the locus of interest.
  • the inclusion of a Neomycin resistance marker in the targeting construct allows for selection of recombinants following transfection of ES cells.
  • Mouse embryonic stems cells were expanded from a pass 13 stock following estabUshed ES cell culture protocols.
  • the targeting plasmid was linearized and electroporated into the ES cells under a range of DNA concentrations (10-40ug per electroporation). Following 14 days of selection on 150ug/ml G418 antibiotic, a total of 480 colonies were picked into 96-well plates for expansion, freezing, and genetic analysis.
  • Clones were screened by PCR and Southern blotting for correct targeted integration of the recombinant allele.
  • the PCR screening strategy was designed to amplify a fragment spanning the short arm of the construct (Metaxin exons 8-4) with one primer in vector sequence and the second primer in the mouse genomic DNA downstream of the short arm and thus outside of the construct. Only correctly integrated plasmid would be amplified and two PCR-positive clones were selected for confi ⁇ nation by Southern blotting.
  • a genomic DNA probe 3' to the construct (Seq. ID Nos. 10 and 11) and a restriction digest exploiting an internal Sea I cutsite introduced by the neomycin selectable marker, the two correctly targeted clones were confirmed.
  • the two confirmed clones were then subjected to a second round of electroporation and selection to remove the neomycin marker in preparation for blastocyst injection.
  • the recombinant ES cells were electroporated with the Flpe recombinase expression plasmid, pCAGGS-Flpe, and transiently selected with lug ml puromycin for 48 hours. Five days after replating at low density, 600 colonies were picked and split to pairs of 96-well plates. One plate of each pair was selected with 200ug/ml G418 to select for neomycin sensitive (Flpe recombined) clones.
  • Example 3 The final ES cell clones, containing one GBA locus altered to include loxP sites flanking exons 8-1 l(FloxGBA), were used to create chimeras by blastocyst injection. Using estabUshed techniques, the FloxGBA Rl ES cells were injected into the inner cell mass of day 3.5 blastocysts harvested from superovulated females. As the Rl ES ceU line originated from (129Sv x 129/J)F1 hybrid mice displaying an agouti coat, C57BL/6J (black) blastocysts were utilized for the injection.
  • the blastocysts developed into chimeric mice displaying a patchwork mix of agouti and black coat colours.
  • Three chimeras displaying a high degree of agouti coat were bread to C57BL/6J mice to produce animals 100% hetero:zygous for the FloxGBA allele.
  • These mice possess the conditional glucocerebrosidase knockout in the presence of Cre-recombinase when bred to homozygosity.
  • mice with a combination of ubiquitous and hematopoietic cell-specific knockout are obtained are obtained utilizing the Tie2-Cre (B6.Cg-Tg(Tekcre) 12Flv) mouse expressing Cre under control of the receptor tyrosine kinase Tek promoter/enhancer (Koni et al. 2001).
  • Cre expression in this animal is limited to endotheUal and hematopoietic cells and the female germline, aUowing for tissue specific knockout of the GBA locus in the first generation and ubiquitous recombination when the FloxGBA aUele is transmitted through the maternal lineage to the second generation.
  • the FloxGBA allele wiU recombine to produce a non-functional GBA aUele only in those tissues expressing Cre (Fig. ID).
  • a hematopoietic ceU-specific knockout leads to glucocerebroside storage in circulating macrophages and subsequent deposition of these "Gaucher cells" in the Uver, spleen, and bone marrow of these mice.
  • the model recapitulates the major visceral symptoms associated with human Gaucher disease while avoiding the lethal epidermal abnormaUties observed in traditional knockout animals.
  • the abiUty to generate ubiquitous knockout mice through the maternal lineage also serves as a control to show that total knockout of the locus is, in fact, lethal in this model system.
  • Numerous other Cre expression strategies targeting other tissues, or under temporal control, could be utilized to explore the complexities of sphingoUpid metaboUsm in the mouse. This would include the use of Uver specific CRE expression, CNS specific CRE expression, epidermal specific CRE expression and partial ubiquitous CRE expression. Branda, supra, Nagy, A. and Mar, L.
  • Example 5 Initial chimeric mice and the hetero and homozygotes produced from further matings are genotyped using a combination of PCR and Southern blot analyses.
  • Our starting point for Cre expression studies was a homozygous FloxGBA mouse.
  • affected tissues liver, spleen, bone marrow, brain, etc.
  • normal tissue pathology is estabUshed as well as activity levels of GBA and other marker enzymes in these and control mice.
  • An important detail in this portion of the work is the estabUshment of the extent and distribution of the Cre-recombinase mediated excision events in these mice.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un modèle de souris recombinant dans lequel le génome de la souris est modifié par introduction de sites de reconnaissance de recombinase en pair dans le gène glucocérébrosidase dans le génome de la souris transgénique que l'on utilise pour estimer la carence en glucocérébrosidase. Les sites de reconnaissance de la recombinase touchent une partie du gène de la glucocérébrosidase comprenant au moins un exon du gène de glucocérébrosidase et sont orientés de manière à exciser une partie du gène de glucocérébrosidase en présence d'une recombinase reconnaissant les sites de reconnaissance de recombinase en pair. Après exposition à la recombinase souhaitée, la souris produit une glucocérébrosidase défectueuse d'une manière contrôlée dans le temps, dans l'espace ou spécifique à un type cellulaire.
PCT/CA2005/000266 2004-02-24 2005-02-24 Modele de souris transgenique et procede d'evaluation de carences en glucocerebrosidase WO2005080574A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54698604P 2004-02-24 2004-02-24
US60/546,986 2004-02-24

Publications (1)

Publication Number Publication Date
WO2005080574A1 true WO2005080574A1 (fr) 2005-09-01

Family

ID=34886284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/000266 WO2005080574A1 (fr) 2004-02-24 2005-02-24 Modele de souris transgenique et procede d'evaluation de carences en glucocerebrosidase

Country Status (1)

Country Link
WO (1) WO2005080574A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105788B2 (en) 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020170076A1 (en) * 1997-05-30 2002-11-14 Susan M. Dymecki Use of flp recombinase in mice
WO2003025161A1 (fr) * 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020170076A1 (en) * 1997-05-30 2002-11-14 Susan M. Dymecki Use of flp recombinase in mice
WO2003025161A1 (fr) * 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRANDA C.S. ET AL: "Talking about a revolution: the impact of site-specific recombinase on genetic analyses in mice.", DEV.CELL, vol. 6, January 2004 (2004-01-01), pages 7 - 28, XP002994211, DOI: doi:10.1016/S1534-5807(03)00399-X *
DYMECKI S.M. ET AL: "Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice.", PROC.NATL.ACAD.SCI.USA., vol. 93, June 1996 (1996-06-01), pages 6191 - 6196, XP002986503, DOI: doi:10.1073/pnas.93.12.6191 *
ORBAN P.C. ET AL: "Tissue-and-site-specific DNA recombination in transgenic mice.", PROC.NATL.ACAD.SCI.USA., vol. 89, August 1992 (1992-08-01), pages 6861 - 6865, XP002914716 *
RODRIGUEZ C.I. ET AL: "High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP.", NAT. GENET., vol. 25, June 2000 (2000-06-01), pages 139 - 140, XP003034016, DOI: doi:10.1038/75973 *
SAUER B. ET AL: "Inducible gene targeting in mice using the Cre//ox system.", METHODS: A COMPANION TO METHODS IN ENZYMOLOGY., vol. 14, 1998, pages 381 - 392, XP001019712, DOI: doi:10.1006/meth.1998.0593 *
UTOMO ARH ET AL: "Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice.", NAT.BIOTECHNOL., vol. 17, November 1999 (1999-11-01), pages 1091 - 1096, XP002186984, DOI: doi:10.1038/15073 *
XU Y.H. ET AL: "Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.", AM.J.PHATOL., vol. 163, no. 5, November 2003 (2003-11-01), pages 2093 - 2101 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105788B2 (en) 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith

Similar Documents

Publication Publication Date Title
JP5320546B2 (ja) Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
US20240368628A1 (en) Targeted gene editing platform independent of dna double strand break and uses thereof
JP6279562B2 (ja) 条件付きノックアウト対立遺伝子を生成するための方法および組成物
EP3585162B1 (fr) Rongeurs comprenant un locus ttr humanisé et procédés d'utilisation
IL265669A (en) Non-human animals with a hexanucleotide repeat expansion at the C9ORF72 position
CA2135313A1 (fr) Methodes pour l'obtention d'animaux transgeniques, comportant un chromosome artificiel de levure
US11891618B2 (en) Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CN111936628B (zh) 阿尔茨海默病动物模型及其应用
US12201096B2 (en) Non-human animals comprising a humanized coagulation factor 12 locus
US11622547B2 (en) Genetically modified mouse that expresses human albumin
US12250931B2 (en) Genetically modified mouse with a humanized PNPLA3 gene and methods of use
EP2363470A1 (fr) Procédé d'introduction d'un gène muté, gène présentant ladite mutation introduite, cassette destinée à l'introduction de la mutation, vecteur destiné à l'introduction de la mutation et mammifère non humain "knock-in"
Camus et al. Unexpected behavior of a gene trap vector comprising a fusion between the Sh ble and the lacZ genes
WO2005080574A1 (fr) Modele de souris transgenique et procede d'evaluation de carences en glucocerebrosidase
US20250163473A1 (en) Targeted gene editing platform independent of dna double strand break and uses thereof
US20090007283A1 (en) Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein
Pownall Creation and analysis of protein tyrosine phosphatase epsilon mutant mice
JPH1132627A (ja) Ｓｅｚ−６遺伝子発現が抑制された哺乳動物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载